These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 20415597)

  • 1. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
    Whiteside TL
    Expert Opin Biol Ther; 2010 Jul; 10(7):1019-35. PubMed ID: 20415597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell modulation by cyclophosphamide for tumour therapy.
    Hughes E; Scurr M; Campbell E; Jones E; Godkin A; Gallimore A
    Immunology; 2018 May; 154(1):62-68. PubMed ID: 29460448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directing Traffic: How to Effectively Drive T Cells into Tumors.
    Anandappa AJ; Wu CJ; Ott PA
    Cancer Discov; 2020 Feb; 10(2):185-197. PubMed ID: 31974169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for colorectal cancer.
    Koido S; Ohkusa T; Homma S; Namiki Y; Takakura K; Saito K; Ito Z; Kobayashi H; Kajihara M; Uchiyama K; Arihiro S; Arakawa H; Okamoto M; Gong J; Tajiri H
    World J Gastroenterol; 2013 Dec; 19(46):8531-42. PubMed ID: 24379570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
    Galluzzi L; Buqué A; Kepp O; Zitvogel L; Kroemer G
    Cancer Cell; 2015 Dec; 28(6):690-714. PubMed ID: 26678337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy.
    Luo W; Zheng L; Zhang T
    Int Immunopharmacol; 2021 Jan; 90():107199. PubMed ID: 33246828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy.
    Hussain M; Javeed A; Ashraf M; Al-Zaubai N; Stewart A; Mukhtar MM
    Pharmacol Res; 2012 Jul; 66(1):7-18. PubMed ID: 22449788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
    Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
    Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
    Janji B; Berchem G; Chouaib S
    Front Immunol; 2018; 9():887. PubMed ID: 29922284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating costimulatory agonists to optimize immune-based cancer therapies.
    Pardee AD; Wesa AK; Storkus WJ
    Immunotherapy; 2009 Mar; 1(2):249-64. PubMed ID: 20046961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.